Article | October 19, 2022

The ABCs Of Transitioning PK Assays From Preclinical To Clinical

Source: Worldwide Clinical Trials

By Dr. Tom Zhang, Chief Scientist, Large Molecule Bioanalysis, Worldwide Clinical Trials

GettyImages-157742535-molecule

Ensuring a seamless transition from preclinical to clinical stages in large molecule bioanalysis will help you reach crucial trial milestones on time and within budget. However, optimizing pharmacokinetics (PK) assays to bridge the preclinical-to-clinical gap requires some finesse. This is because the stages differ both in scale (small vs. large) and focus (safety vs. safety and efficacy).

Explore a few points to jumpstart your thinking as you approach this challenge.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader